CHOSA - The market now doubles for Platin-DRP®, which predicts overall survival in lung cancer patients based on NanoString data

On Dec. 11, 2025 CHOSA Oncology reported that its Platin-DRP® biomarker, implemented on the NanoString transcriptomic platform, significantly predicts overall survival in non‑small cell lung cancer patients treated with platinum chemotherapy and shows high concordance with the original Affymetrix-based signature from the ETOP/EORTC SPLENDOUR study. Higher Platin-DRP scores were significantly associated with longer overall survival in both the carboplatin cohort and the pooled platinum-treated population, while objective response rates were not correlated, emphasizing survival as the clinically relevant endpoint. CHOSA says cross‑platform validation more than doubles the addressable market (per Mordor Intelligence) and is pursuing further analytical validation, regulatory discussions and commercialization, positioning the test to inform platinum use and potential combinations with PD‑1/L1 inhibitors.

Analysis

On Dec. 11, 2025 CHOSA Oncology reported that its Platin-DRP® biomarker implemented on the NanoString transcriptomic platform significantly predicts overall survival in non-small cell lung cancer (NSCLC) patients treated with platinum chemotherapy, and that NanoString-based scores show high correlation with the original Affymetrix signature from the ETOP/EORTC SPLENDOUR study announced Sept. 30, 2025. Higher Platin-DRP® scores were statistically significant predictors of longer overall survival in the carboplatin cohort and the pooled platinum-treated population, while objective response rates were not correlated with the transcriptomic score, underscoring survival as the clinically relevant endpoint.

CHOSA states cross-platform validation more than doubles the addressable market for Platin-DRP® per Mordor Intelligence, and the company is engaging in regulatory discussions and preparing for commercialization with further analytical validation and alignment with international lung-cancer experts. The Cisplatin-DRP is a 205-gene signature with prior retrospective data showing patients in the top 10% score had a 3-year survival of 90% versus 40% in the lowest 10%, supporting the biomarker's potential clinical differentiation.

Key near-term issues are execution and evidentiary risk: analytical validation on NanoString, regulatory alignment, prospective or regulatory-grade validation and reimbursement pathways are not yet complete, which limits immediate commercial uptake. The data enhance the case for the DRP as a companion predictive tool—particularly for potential combinations with PD-1/L1 inhibitors—but market impact remains contingent on regulatory, reimbursement and partnership outcomes.

Key Decisions for Investors

• Monitor CHOSA's upcoming analytical-validation and regulatory milestones (NanoString validation readouts, formal regulatory discussions and any prospective study initiations), as positive developments are the primary short-term catalysts
• Factor the reported >2x addressable market into valuation but apply a significant execution discount until regulatory clearance and reimbursement pathways are clearer, consider small or staged exposure rather than full allocation
• Prioritize future data that demonstrate prospective survival benefit or regulatory acceptance over improvements in objective response rate, since the announcement emphasizes overall survival as the clinically relevant endpoint
• For holders of related licenses or Allarity (ALLR) exposure, watch for commercialization or partnership agreements with diagnostics firms, PD-1 inhibitor companies, or payers, as these deals would materially de‑risk commercialization
• Use news-driven intraday or event trades cautiously and consider hedging positions given the binary nature of regulatory outcomes and the currently moderate market-impact signal